Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,850 | -7,087 | -43,270 | -14,029 | -6,204 |
| Depreciation Amortization | 354 | 178 | 887 | 701 | 503 |
| Income taxes - deferred | 0 | 0 | N/A | -1,181 | -169 |
| Accounts receivable | 50,111 | 50,321 | -857 | -104 | N/A |
| Other Working Capital | 22,470 | 27,124 | 21,096 | -195 | -852 |
| Other Operating Activity | -44,243 | -48,632 | -1,417 | -2,880 | -6,118 |
| Operating Cash Flow | $14,842 | $21,904 | $-23,561 | $-17,688 | $-12,840 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -143 | -46 | -340 | -194 | -126 |
| Other Investing Activity | 0 | 0 | 10,085 | 10,085 | 10,085 |
| Investing Cash Flow | $-143 | $-46 | $9,745 | $9,891 | $9,959 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -15 | -8 | -20 | -13 | N/A |
| Common Stock Issued | 635 | 529 | 38,105 | 30,741 | 33,161 |
| Common Stock Repurchased | -17 | -8 | -54 | N/A | -27 |
| Other Financing Activity | -57 | 0 | -1,101 | 5,248 | -877 |
| Financing Cash Flow | $546 | $513 | $36,930 | $35,976 | $32,257 |
| Exchange Rate Effect | -161 | -42 | -20 | -34 | -43 |
| Beginning Cash Position | 56,277 | 56,277 | 33,183 | 33,183 | 33,183 |
| End Cash Position | 71,361 | 78,606 | 56,277 | 61,328 | 62,516 |
| Net Cash Flow | $15,084 | $22,329 | $23,094 | $28,145 | $29,333 |
| Free Cash Flow | |||||
| Operating Cash Flow | 14,842 | 21,904 | -23,561 | -17,688 | -12,840 |
| Capital Expenditure | -143 | -46 | -340 | -194 | -126 |
| Free Cash Flow | 14,699 | 21,858 | -23,901 | -17,882 | -12,966 |